Proteomics International Laboratories (ASX:PIQ) received a patent from the Canadian Patent Office for its PromarkerEso, a blood test to rule out esophageal cancer caused by chronic acid reflux in patients, according to a Friday Australian bourse filing.
The granted patent provides intellectual property protection for PromarkerEso in Canada until Nov. 17, 2035, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.